Gland Pharma Q4 Results 2025 Preview: Steady Growth Expected on Strong US Sales, New Launches; Share Price Up

Global pharmaceutical major Gland Pharma Ltd. is set to announce its financial results for the January-March quarter and the full year ending 2025 (Q4 FY25) on Tuesday. Market analysts expect a steady performance from the company during this period, supported by key product shipments, new launches, and stable pricing. Should you buy, hold, or sell this pharma stock? Here's a look at what top brokerages are forecasting and what investors can expect.

Gland Pharma Q4 Results 2025 Today

Even though the fourth quarter is usually slow for pharmaceutical companies, Gland Pharma is likely to do better this time. This is due to a few factors, such as delayed shipments being delivered, new product launches, and a slow but steady recovery in its overseas markets.

One major reason for the expected good performance is strong sales in the US, especially from the generic version of Revlimid (gRevlimid). In addition, the company's domestic sales are growing, with an increasing share of chronic disease treatments contributing to the growth.

Gland Pharma Q4 Results 2025 Preview

According to Bloomberg estimates, Gland Pharma's net profit for the March 2025 quarter is expected to rise by 21.28% year-on-year to Rs 233.36 crore, compared to Rs 192.42 crore in the same quarter last year. Consolidated revenue is projected to increase slightly by 0.9% to Rs 1,551.73 crore from Rs 1,537.45 crore.

Gland Pharma EBITDA: Earnings before interest, taxes, depreciation, and amortization (Ebitda) are expected to grow by 5.54% to Rs 376.14 crore, up from Rs 356.39 crore, while the operating margin is likely to improve to 24.2% from 23.3% a year ago.

Pharma Stocks in Focus Today: Should You Buy Gland Pharma Stock? Check Analyst's Rating

IIFL Capital has given an "Add" rating on Gland Pharma with a target price of Rs 1,650. According to the brokerage, Gland Pharma's India business is mainly focused on the B2B segment. The company's quarter-on-quarter growth is expected to benefit from the deferral of key product shipments, such as Enoxaparin and Ketorolac, from the third quarter to the fourth. This momentum is likely to be further boosted by the scale-up of new product launches and limited impact from price erosion.

Gland Pharma Share Price Today

Gland Pharma Ltd.'s stock is currently priced at 1,501.00 INR, up by Rs 17.10 or 1.15% as of 10:54 AM on May 20. The stock opened at Rs 1,491.70 and has reached a high of 1,514.90 INR and a low of Rs 1,488.10 during the day.

Gland Pharma Stock Performance Today: The company's market capitalization stands at 24.70K crore, reflecting its total value in the stock market. The P/E ratio is 35.11, indicating that investors are willing to pay 35.11 times the company's earnings for each share. Gland Pharma also offers a dividend yield of 1.33%, meaning shareholders can expect a return of 1.33% of their investment through dividends. Over the past year, the stock has fluctuated between a 52-week high of Rs 2,220.95 and a 52-week low of Rs 1,277.80.

Take a Poll

Pharma Sector Performance Q4 FY2025

Among the peers, Dr. Reddy's Laboratories posted a 22% year-on-year rise in consolidated net profit to Rs 1,594 crore, with revenue increasing by 20% to Rs 8,506 crore . Cipla reported a 30% increase in net profit to Rs 1,222 crore, with revenue up 8.5% to Rs 6,730 crore . Divi's Laboratories saw a 26% rise in net profit to Rs 667 crore, accompanied by a 12% increase in revenue to Rs 2,536 crore . Abbott India experienced a 28% growth in net profit to Rs 367 crore, with revenue rising 11.5% to Rs 1,605 crore .

These figures indicate that while Gland Pharma's performance was positive, its growth rates were relatively modest compared to some of its larger peers in the Indian pharmaceutical sector during the same period.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.